Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2025 | 03-2024 | 03-2023 | 03-2022 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 713,744 | 994,959 | 2,346,081 | 2,048,477 | 3,536,007 |
| Depreciation Amortization | 5,025,213 | 5,023,214 | 4,916,560 | 5,190,044 | 5,260,907 |
| Accounts receivable | -389,129 | 104,218 | 555,940 | 1,132,917 | -87,570 |
| Accounts payable and accrued liabilities | -46,979 | -68,276 | -627,550 | 1,113,897 | 344,228 |
| Other Working Capital | -391,855 | -1,818,557 | -843,911 | 877,585 | 2,592,341 |
| Other Operating Activity | 2,066,408 | 707,215 | 883,835 | -367,285 | -2,143,162 |
| Operating Cash Flow | $6,977,401 | $4,942,773 | $7,230,955 | $9,995,635 | $9,502,751 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,324,732 | -1,151,017 | -1,033,743 | -1,080,789 | -608,678 |
| Net Acquisitions | 135,670 | 137,717 | 58,889 | -191,136 | 4,985,647 |
| Purchase Of Investment | -650,364 | -46,685 | -75,117 | -74,235 | -118,402 |
| Sale Of Investment | 575,078 | 55,345 | 164,680 | 150,597 | 701,278 |
| Purchase Sale Intangibles | -1,180,278 | -2,106,639 | -3,648,437 | -558,787 | -1,177,463 |
| Other Investing Activity | -1,158,247 | -2,196,008 | -3,607,263 | -567,750 | -1,260,662 |
| Investing Cash Flow | $-2,422,596 | $-3,200,648 | $-4,492,555 | $-1,763,313 | $3,699,182 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 6,761,436 | 690,000 | 555,000 | 2,219,073 | 11,087,440 |
| Debt Repayment | -8,719,194 | -2,214,217 | -2,639,358 | -7,210,023 | -15,526,040 |
| Common Stock Repurchased | -342,276 | -16,049 | -199,275 | -690,026 | -20,125 |
| Dividend Paid | -1,996,487 | -1,981,597 | -2,067,678 | -2,524,618 | -2,663,556 |
| Other Financing Activity | -662,884 | 1,076,393 | -896,384 | -1,319,764 | -3,108,249 |
| Financing Cash Flow | $-4,959,405 | $-2,445,470 | $-5,247,695 | $-9,525,358 | $-10,230,530 |
| Exchange Rate Effect | -75,141 | 180,808 | 169,675 | 255,946 | 117,509 |
| Beginning Cash Position | 3,021,480 | 3,681,357 | 6,287,743 | 8,599,376 | 5,993,572 |
| End Cash Position | 2,541,746 | 3,158,820 | 3,948,122 | 7,562,286 | 9,082,486 |
| Net Cash Flow | $-479,734 | $-522,537 | $-2,339,621 | $-1,037,090 | $3,088,915 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,977,401 | 4,942,773 | 7,230,955 | 9,995,635 | 9,502,751 |
| Capital Expenditure | -1,325,247 | -1,210,398 | -1,040,862 | -1,096,943 | -1,045,336 |
| Free Cash Flow | 5,652,154 | 3,732,375 | 6,190,093 | 8,898,692 | 8,457,415 |